205 related articles for article (PubMed ID: 32571464)
21. Cut-off values of immunological tests to identify patients at high risk of severe lupus nephritis.
Gargiulo MLÁ; Khoury M; Gómez G; Grimaudo S; Suárez L; Collado MV; Sarano J
Medicina (B Aires); 2018; 78(5):329-335. PubMed ID: 30285925
[TBL] [Abstract][Full Text] [Related]
22. Comparison of circulating miR-148a and miR-126 with autoantibodies as biomarkers of lupus nephritis in patients with SLE.
Omidi F; Khoshmirsafa M; Kianmehr N; Faraji F; Delbandi A; Seif F; Shekarabi M
J Immunoassay Immunochem; 2022 Nov; 43(6):634-647. PubMed ID: 35938736
[TBL] [Abstract][Full Text] [Related]
23. Circulating Exosomal microRNAs as Biomarkers of Systemic Lupus Erythematosus.
Li W; Liu S; Chen Y; Weng R; Zhang K; He X; He C
Clinics (Sao Paulo); 2020; 75():e1528. PubMed ID: 32876110
[TBL] [Abstract][Full Text] [Related]
24. Anti-C1q autoantibodies as markers of renal involvement in childhood-onset systemic lupus erythematosus.
Picard C; Lega JC; Ranchin B; Cochat P; Cabrera N; Fabien N; Belot A
Pediatr Nephrol; 2017 Sep; 32(9):1537-1545. PubMed ID: 28343355
[TBL] [Abstract][Full Text] [Related]
25. Polyomavirus BK, BKV microRNA, and urinary neutrophil gelatinase-associated lipocalin can be used as potential biomarkers of lupus nephritis.
Li YJ; Wu HH; Liu SH; Tu KH; Lee CC; Hsu HH; Chang MY; Yu KH; Chen W; Tian YC
PLoS One; 2019; 14(1):e0210633. PubMed ID: 30640964
[TBL] [Abstract][Full Text] [Related]
26. Combined detection of uMCP-1 and uTWEAK for rapid discrimination of severe lupus nephritis.
Dong XW; Zheng ZH; Ding J; Luo X; Li ZQ; Li Y; Rong MY; Fu YL; Shi JH; Yu LC; Wu ZB; Zhu P
Lupus; 2018 May; 27(6):971-981. PubMed ID: 29451067
[TBL] [Abstract][Full Text] [Related]
27. Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement.
Oelzner P; Deliyska B; Fünfstück R; Hein G; Herrmann D; Stein G
Clin Rheumatol; 2003 Oct; 22(4-5):271-8. PubMed ID: 14576989
[TBL] [Abstract][Full Text] [Related]
28. miR-152 Attenuates the Severity of Lupus Nephritis Through the Downregulation of Macrophage Migration Inhibitory Factor (MIF)-Induced Expression of COL1A1.
Zheng J; Guo R; Tang Y; Fu Q; Chen J; Wu L; Leng L; Bucala R; Song Y; Lu L
Front Immunol; 2019; 10():158. PubMed ID: 30787934
[No Abstract] [Full Text] [Related]
29. Urinary angiostatin, CXCL4 and VCAM-1 as biomarkers of lupus nephritis.
Mok CC; Soliman S; Ho LY; Mohamed FA; Mohamed FI; Mohan C
Arthritis Res Ther; 2018 Jan; 20(1):6. PubMed ID: 29325582
[TBL] [Abstract][Full Text] [Related]
30. Plasma levels of miR-21, miR-150, miR-423 in patients with lupus nephritis.
Nakhjavani M; Etemadi J; Pourlak T; Mirhosaini Z; Zununi Vahed S; Abediazar S
Iran J Kidney Dis; 2019 May; 13(3):198-206. PubMed ID: 31209193
[TBL] [Abstract][Full Text] [Related]
31. Serum Levels of CXCL10 and Vitamin D in Patients with Lupus Nephritis.
Abediazar S; Jafari-Nakhjavani M; Ghorbanihaghjo A; Shekarchi M; Zununi Vahed S
Iran J Kidney Dis; 2019 Nov; 13(6):389-397. PubMed ID: 31880585
[TBL] [Abstract][Full Text] [Related]
32. Altered levels of immune-regulatory microRNAs in plasma samples of patients with lupus nephritis.
Zununi Vahed S; Nakhjavani M; Etemadi J; Jamshidi H; Jadidian N; Pourlak T; Abediazar S
Bioimpacts; 2018; 8(3):177-183. PubMed ID: 30211077
[No Abstract] [Full Text] [Related]
33. Platelet distribution width as a marker for predicting lupus nephritis.
Yu H; Jiang L; Liu R; Sheng L; Ji P
Int Immunopharmacol; 2020 Aug; 85():106693. PubMed ID: 32559723
[TBL] [Abstract][Full Text] [Related]
34. Plasma immunoglobulin binding protein 1 as a predictor of development of lupus nephritis.
Kwon OC; Lee EJ; Oh JS; Hong S; Lee CK; Yoo B; Park MC; Kim YG
Lupus; 2020 May; 29(6):547-553. PubMed ID: 32183589
[TBL] [Abstract][Full Text] [Related]
35. The clinical significance of plasma CFHR 1-5 in lupus nephropathy.
Hu X; Liu H; Du J; Chen Y; Yang M; Xie Y; Chen J; Yan S; Ouyang S; Gong Z
Immunobiology; 2019 May; 224(3):339-346. PubMed ID: 30975435
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-32γ: Possible association with the activity and development of nephritis in patients with systemic lupus erythematosus.
Kwon OC; Ghang B; Lee EJ; Hong S; Lee CK; Yoo B; Kim S; Kim YG
Int J Rheum Dis; 2019 Jul; 22(7):1305-1311. PubMed ID: 30941928
[TBL] [Abstract][Full Text] [Related]
37. Downregulated miR-203 attenuates IL-β, IL-6, and TNF-α activation in TRAF6-treated human renal mesangial and tubular epithelial cells.
Zhang L; Zhang X
Int J Clin Exp Pathol; 2020; 13(2):324-331. PubMed ID: 32211116
[TBL] [Abstract][Full Text] [Related]
38. Regulation of MiR-146a and TRAF6 in the Diagnose of Lupus Nephritis.
Zhu Y; Xue Z; Di L
Med Sci Monit; 2017 May; 23():2550-2557. PubMed ID: 28549054
[TBL] [Abstract][Full Text] [Related]
39. Relationship between Blood Lipid Profiles and Risk of Lupus Nephritis in Children.
Liu J; Song W; Cui D
Int J Clin Pract; 2022; 2022():6130774. PubMed ID: 36349053
[TBL] [Abstract][Full Text] [Related]
40. Plasma C4d Correlates With C4d Deposition in Kidneys and With Treatment Response in Lupus Nephritis Patients.
Martin M; Trattner R; Nilsson SC; Björk A; Zickert A; Blom AM; Gunnarsson I
Front Immunol; 2020; 11():582737. PubMed ID: 33133102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
